BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38054534)

  • 21. Cytokine-enhanced cytolytic activity of exosomes from NK Cells.
    Enomoto Y; Li P; Jenkins LM; Anastasakis D; Lyons GC; Hafner M; Leonard WJ
    Cancer Gene Ther; 2022 Jun; 29(6):734-749. PubMed ID: 34316033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy.
    Granzin M; Soltenborn S; Müller S; Kollet J; Berg M; Cerwenka A; Childs RW; Huppert V
    Cytotherapy; 2015 May; 17(5):621-32. PubMed ID: 25881519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoregulatory functions and therapeutic potential of natural killer cell-derived extracellular vesicles in chronic diseases.
    He S; Su L; Hu H; Liu H; Xiong J; Gong X; Chi H; Wu Q; Yang G
    Front Immunol; 2023; 14():1328094. PubMed ID: 38239346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced extracellular vesicle production and ethanol-mediated vascularization bioactivity via a 3D-printed scaffold-perfusion bioreactor system.
    Patel DB; Luthers CR; Lerman MJ; Fisher JP; Jay SM
    Acta Biomater; 2019 Sep; 95():236-244. PubMed ID: 30471476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
    Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy.
    Lu YC; Ho CH; Hong JH; Kuo MC; Liao YA; Jaw FS; Cheng JC; Huang CY; Chang KP; Chen CH; Lin JA; Hsiao A; Kung HN
    Mol Oncol; 2023 Aug; 17(8):1613-1627. PubMed ID: 36931723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
    Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
    Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CTLs, NK cells and NK-derived EVs against breast cancer.
    Parsonidis P; Mamagkaki A; Papasotiriou I
    Hum Immunol; 2023; 84(5-7):320-326. PubMed ID: 36925436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. iPSCs in NK Cell Manufacturing and NKEV Development.
    Boyd-Gibbins N; Karagiannis P; Hwang DW; Kim SI
    Front Immunol; 2022; 13():890894. PubMed ID: 35874677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process.
    Spanholtz J; Preijers F; Tordoir M; Trilsbeek C; Paardekooper J; de Witte T; Schaap N; Dolstra H
    PLoS One; 2011; 6(6):e20740. PubMed ID: 21698239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
    Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
    PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18.
    Aarsund M; Segers FM; Wu Y; Inngjerdingen M
    Cancer Immunol Immunother; 2022 Sep; 71(9):2227-2238. PubMed ID: 35119498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
    Zhu H; Kaufman DS
    Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy.
    Zhang J; Sun R; Wei H; Zhang J; Tian Z
    Oncol Rep; 2004 May; 11(5):1097-106. PubMed ID: 15069553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
    Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
    Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
    Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Scalable Enrichment of Immunomodulatory Human Acute Myeloid Leukemia Cell Line-Derived Extracellular Vesicles.
    Binder HM; Maeding N; Wolf M; Cronemberger Andrade A; Vari B; Krisch L; Gomes FG; Blöchl C; Muigg K; Poupardin R; Raninger AM; Heuser T; Obermayer A; Ebner-Peking P; Pleyer L; Greil R; Huber CG; Schallmoser K; Strunk D
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
    Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
    Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.